PaxMedica (PXMD) Stock Price, News & Analysis

Company Overview

PaxMedica, Inc. is a clinical‐stage biopharmaceutical company headquartered in Burlingame, California. The company is dedicated to developing novel therapies for central nervous system disorders, with a particular emphasis on addressing unmet needs in autism spectrum disorders, mood disorders and related behavioral conditions. PaxMedica focuses on small-molecule candidates designed to modulate key neural pathways implicated in social and emotional regulation.

The company’s lead development program centers on arbaclofen, a proprietary formulation intended to improve social functioning in patients with autism spectrum disorders and associated behavioral challenges. PaxMedica has advanced preclinical and initial clinical work to assess the safety, tolerability and efficacy of this candidate. The company’s research activities leverage collaborations with academic centers and contract research organizations to support its translational pipeline and exploratory biomarker studies.

Founded in 2015, PaxMedica has assembled a management team with experience in neuroscience drug development and regulatory strategy. While the company’s primary operations are based in the United States, its clinical trial plans include potential international sites to facilitate patient enrollment. PaxMedica continues to build its pipeline through in-licensing and internal discovery efforts aimed at expanding therapeutic options for patients with challenging neurobehavioral conditions.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 3,388 shs
• Market Capitalization: $2 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PXMD Stock Analysis - Frequently Asked Questions

When did PaxMedica's stock split?

PaxMedica's stock reverse split on the morning of Tuesday, October 31st 2023.The 1-17 reverse split was announced on Monday, October 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did PaxMedica IPO?

PaxMedica (PXMD) raised $9 million in an initial public offering on Friday, August 26th 2022. The company issued 1,600,000 shares at a price of $4.50-$6.50 per share. Craft Capital Management and R.F.Lafferty & Co. served as the underwriters for the IPO.

How do I buy shares of PaxMedica?

Shares of PXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PaxMedica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PaxMedica investors own include Pfizer (PFE), PayPal (PYPL), Oracle (ORCL), Arista Networks (ANET), Avino Silver & Gold Mines (ASM) and Corbus Pharmaceuticals (CRBP).

Company Calendar

• Today: 10/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PXMD
• CIK: 1811623
• Web: www.paxmedica.com
• Phone: 914-987-2876
• Fax: N/A
• Employees: 2
• Year Founded: 2018

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -3,167.89%
• Return on Assets: -560.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.38
• Quick Ratio: 0.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.46 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 11,312,000
• Free Float: 11,199,000
• Market Cap: $2 thousand
• Optionable: Not Optionable
• Beta: -0.99